Market Place
Sourcing Support
Essa Pharma Terminates Ph 2 Study of Masofaniten in Prostate Cancer
31 Oct 2024 //
PR NEWSWIRE
J&J`s Erleada shows survival edge over Xtandi in real-world study
02 Oct 2024 //
FIERCE PHARMA
ESSA Pharma Reports Q3 2024 Financial Results And Updates
05 Aug 2024 //
PR NEWSWIRE
Nanoform Bio-Nanoparticles Showcased Large Pharma Partnering Progresses
30 May 2024 //
PR NEWSWIRE
Fibrogen Fg-3246 Interim Phase 1b: Mcrpc Positive With Enzalutamide
23 May 2024 //
GLOBENEWSWIRE
FibroGen`s FG-3246 + Enzalutamide Data at ASCO 2024
24 Apr 2024 //
GLOBENEWSWIRE
Astellas` XTANDI Approved in EU for Early Prostate Cancer
23 Apr 2024 //
PR NEWSWIRE
Astellas Receives +ve Opinion for XTANDI for Early Prostate Cancer Treatment
22 Mar 2024 //
PR NEWSWIRE
Nanoform Announces Milestone with Promising Clinical Results for Enzalutamide
26 Jan 2024 //
PR NEWSWIRE
EC Approves Pfizer’s TALZENNA®with XTANDI® for Prostate Cancer
08 Jan 2024 //
BUSINESSWIRE
Nanoform Commenced Relative Bioavailability Study of Enzalutamide
05 Jan 2024 //
PR NEWSWIRE
Pfizer & Astellas` XTANDI Approved by FDA in Earlier Prostate Cancer Treatment
17 Nov 2023 //
PR NEWSWIRE
Humanwell Puracap`s Generic Enzalutamide Receives Approval in the U.S.
25 Sep 2023 //
FDA
ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten
18 Sep 2023 //
PR NEWSWIRE
European Medicines Agency Validates Type II Variation for Astellas` XTANDI
12 Sep 2023 //
PR NEWSWIRE
FDA Grants Priority Review for XTANDI in nmHSPC
23 Aug 2023 //
PR NEWSWIRE
FDA Approves Talazoparib Plus Enzalutamide for HRR Gene–Altered mCRPC
20 Jun 2023 //
ONCOLIVE
Pfizer, Astellas detail Xtandi win in earlier prostate cancer
02 May 2023 //
FIERCE PHARMA
XTANDI® plus Leuprolide Reduced Risk of Metastasis by 58% NMHS Prostate Cancer
29 Apr 2023 //
PR NEWSWIRE
Patients appeal NIH`s rejection to use `march-in` rights on Astellas` Xtandi
23 Mar 2023 //
ENDPTS
US declines to force lower price on cancer drug Xtandi
22 Mar 2023 //
REUTERS
Astellas, Pfizer eye new prostate cancer use for Xtandi
18 Mar 2023 //
FIERCE PHARMA
Pfizer`s Talzenna staves off prostate cancer in showdown with AZ, J&J
17 Feb 2023 //
FIERCE PHARMA
Merck Announces KEYNOTE-991 Trial Evaluating KEYTRUDA Plus Enzalutamide
25 Jan 2023 //
PRESS RELEASE
Legislators call HHS to action on Xtandi march-in rights
11 Jan 2023 //
ENDPTS
Results from Ph 1/2 Study of EPI-7386 with Enzalutamide Highlighted at Retreat
26 Oct 2022 //
PRNEWSWIRE
POINT Provides Updated Safety Data from PIII SPLASH Trial in mCRPC at ESMO 2022
09 Sep 2022 //
GLOBENEWSWIRE
Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program
01 Aug 2022 //
BUSINESSWIRE
March-in` battles heat up as nonprofits petition HHS on 6 drugs petition awaits
26 Mar 2022 //
ENDPTS
BDR Pharma introduces prostate cancer drug with enhanced strength
28 Feb 2022 //
BUSINESS-STANDARD
Warren Urges Government to Seize Patents on Pfizer’s Cancer Drug
22 Feb 2022 //
BLOOMBERGLAW
US FDA clears Nuvation Bio’s application for solid tumour therapy
21 Jan 2022 //
PHARMACEUTICAL-TECHNOLOGY
ESSA Pharma Begins Dosing in Phase 1/2 Clinical Trial of EPI-7386
19 Jan 2022 //
PRNEWSWIRE
Astellas-Pfizer’s Xtandi reduces mortality risk in prostate cancer trial
20 Sep 2021 //
CLINICALTRIALSARENA
Exelixis Announces PIb Results from COSMIC-021 Trial in Metastatic CRPC
18 Sep 2021 //
BUSINESSWIRE
XTANDI® Reduced Risk of Death by 34% in Men with Prostate Cancer
17 Sep 2021 //
PRNEWSWIRE
Astellas` and Pfizer`s XTANDI(R) (enzalutamide) Reduced Risk of Death by 34%
17 Sep 2021 //
SHARECAST
Epizyme Announces Data from TAZVERIK Clinical Programs to be Presented ESMO 2021
14 Sep 2021 //
BUSINESSWIRE
FDA finalizes guidance on metastasis-free survival as an endpoint
06 Aug 2021 //
RAPS
Astellas` Xtandi nabs prostate cancer nod from UK cost watchdog
11 Jun 2021 //
FIERCE PHARMA
FDA gives approval to amivantamab-vmjw in non-small cell lung cancer
10 Jun 2021 //
PHARMATIMES
Astellas` XTANDI™ (enzalutamide) Approved by European Commission
28 May 2021 //
PRNEWSWIRE
Actavis`s Generic Mesalamine Receives Approval in US
18 May 2021 //
FDA
Astellas Receives Positive CHMP Opinion for XTANDI™ (enzalutamide)
16 May 2021 //
PRNEWSWIRE
Astellas’ Xtandi bags additional MHRA approval in prostate cancer
13 May 2021 //
PHARMATIMES
Astellas’ Xtandi bags additional MHRA approval in prostate cancer
12 May 2021 //
PHARMATIMES
Astellas Receives Positive CHMP Opinion for XTANDI™ (enzalutamide)
25 Mar 2021 //
PRNEWSWIRE
ESSA Pharma Announces Clinical Collaboration with Astellas of EPI-7386
24 Feb 2021 //
PRNEWSWIRE
XTANDI® (enzalutamide soft capsules) Approved by China NMPA
06 Nov 2020 //
PRNEWSWIRE
China approves Astellas` Xtandi in non-metastatic -resistant prostate cancer
06 Nov 2020 //
PHARMAFILE
China NMPA approves Astellas Pharma’s Xtandi to treat non-metastatic castration
06 Nov 2020 //
PHARMABIZ
OS Data With Olaparib Herald Practice-Changing Treatment Of met-Prostate Cancer
22 Sep 2020 //
ESMO
BDR launches 80mg version of prostate cancer drug at Rs 24,480 per pack in India
21 Sep 2020 //
ECONOMIC TIMES
Veru Announces Data of VERU-111 Phase 1b Study in Metastatic Prostate Cancer
18 Sep 2020 //
GLOBENEWSWIRE
Enzalutamide has added benefit for men with castration-resistant prostate cancer
19 Aug 2020 //
NEWS-MEDICAL
Kangpu to Present Two Posters at the 2020 (AACR) Annual Meeting
17 Jun 2020 //
PRNASIA
Health Canada Approves XTANDI® (enzalutamide), for the treatment of (mCSPC)¹
16 Jun 2020 //
NEWSWIRE
Final PROSPER Results Show XTANDI® (enzalutamide) Significantly Extends
29 May 2020 //
PRNEWSWIRE
Astellas receives approval for prostate cancer drug
29 May 2020 //
BIOSPECTRUMASIA
XTANDI® (enzalutamide) Approved by Japan MHLW for the of Prostate Cancer
28 May 2020 //
PRNEWSWIRE
